



Antiretroviral Prices in 2023

This publication is a compilation of the prices (in US\$ per person per year) of antiretroviral (ARV) drugs in low- and middle-income countries (LMICs) in 2023, as quoted by the corporations that produce them. The price in brackets corresponds to the price of one unit (tablet, capsule, mL, etc). Products included in the World Health Organization (WHO) list of prequalified medicines or approved by the US Food and Drug Administration (as of November 2023) are in bold. Each originator corporation applies its own eligibility criteria for discounting ARVs. Countries that are eligible for a discount from one corporation may not be eligible for discounts from others. Usually, corporations create two to three groups of discount-eligible countries, often called ‘Category 1’ (countries that are eligible for the highest discounts) and ‘Category 2/3’ (countries that are offered a lower discount).

Paediatric formulations are highlighted in pink. Prices for paediatric products are estimated, based on WHO-recommended dosing, for the 10 kg weight band. When it was not possible to calculate dosing for the 10 kg weight band, the unit price was used.

The prices paid by the Global Fund to Fight AIDS, Tuberculosis and HIV (Global Fund) have been added as a comparison and additional reference. The prices indicated are the lowest reported for each item in the April 2024 update of Global Fund’s Pooled Procurement Mechanism (PPM) prices, which accounts for larger pack sizes and cartonless products where applicable.

The lowest price for WHO’s first-line HIV treatment for adults (TDF/3TC/DTG) is US\$37 per person per year. For WHO’s first-line treatment for children, it is \$30 for the new paediatric fixed-dose combination (FDC) of ABC/3TC/DTG (based on 10kg).

Generic corporations producing dolutegravir (DTG) or DTG-based FDCs provided price ranges, reflecting the royalties imposed for certain countries as per the voluntary license for DTG between pharmaceutical corporation ViiV and the Medicines Patent Pool, and the lowest prices are provided here. Royalties paid by generic manufacturers to ViiV vary by country: 5% in India, Vietnam, Philippines and Moldova; 7.5% in Indonesia, Egypt, Morocco, Armenia and Ukraine; 10% in Turkmenistan.¹

Note that where multiple pack sizes are available (i.e., 30, 90, 180 tabs), with or without cartons, the lowest price is included in the table.

¹ <https://medicinespatentpool.org/licence-post/dolutegravir-adult-dtg>

| ARVs | Daily Dose | Originator Corporation | | Global Fund PPM Prices | | | | | | | | | |
|------------------------------|------------|------------------------|-------------------|------------------------|--------------------|--------------------|--------------------|--------|-------------------|-------|-------------------|-------------------|-------------------|
| atazanavir (ATV) | | BMS | | | Emcure | | | | | | | | |
| | | Cat 1 | Cat 2 | | | | | | | | | | |
| 300mg capsule | 1 | \$1606 (\$4.40) | \$803 (\$2.20) | | \$243 (\$0.667) | | | | | | | | |
| atazanavir/ritonavir (ATV/r) | | No Originator | | Global Fund | Emcure | Lupin | Mylan | | | | | | |
| 300/100mg tablet | 1 | N/A | | \$128 (\$0.35) | \$133 (\$0.365) | \$135 (\$0.370) | \$164 (\$0.450) | | | | | | |
| darunavir (DRV) | | Janssen | | Global Fund | Cipla | Hetero | Mylan | | | | | | |
| | | Cat 1 | Cat 2 | | | | | | | | | | |
| 75mg tablet | 2 | \$82 (\$0.113) | N/A | \$99 (\$0.135) | | | | | | | | | |
| 150mg tablet | 6 | \$493 (\$0.225) | | N/A | | | | | | | | | |
| 400mg tablet | 2 | \$438 (\$0.600) | | \$487 (\$0.667) | | | | | | | | | |
| 600mg tablet | 2 | \$657 (\$0.900) | | \$511 (\$0.700) | \$572 (\$0.783) | \$548 (\$0.750) | \$511 (\$0.700) | | | | | | |
| dolutegravir (DTG) | | ViiV | | Global Fund | Aurobindo | Cipla | Emcure | Hetero | Macleods | Micro | Mylan | Sun | Strides |
| 10mg dispersible tablet | 2 | N/A | | \$33 (\$0.044) | | | | | \$37 (\$0.050) | | \$37 (\$0.050) | | |
| 50mg tablet | 1 | POA ⁱ | | \$15 (\$0.040) | \$22 | \$28 | \$22 (\$0.061) | \$21 | \$77 (\$0.053) | \$23 | \$18 (\$0.049) | \$24 (\$0.065) | \$43 (\$0.117) |

| | | | | | (\$0.06 0) | (\$0.0 77) | | (\$0.0 58) | | (\$0.06 3) | | |
|---------------------------------|----------|--------------------|------------------------|--------------------|------------------------|------------------------|--------------------|------------------------|--|---------------|--|--|
| efavirenz (EFV) | | Merck | | Global Fund | Sun Pharm a | | | | | | | |
| | | Cat 1 | Cat 2 | | | | | | | | | |
| 200mg tablet (single scored) | 3 | \$394 (\$0.360) | N/A | | | | | | | | | |
| 600mg tablet | 1 | \$237 (\$0.650) | N/A | | \$32 (\$0.08 8) | | | | | | | |
| etravirine (ETV) | | Janssen | | Global Fund | | | | | | | | |
| | | Cat 1 | Cat 2 | | | | | | | | | |
| 100mg tablet | 4 | \$438 (\$0.300) | N/A | \$438 (\$0.30) | | | | | | | | |
| lamivudine (3TC) | | ViiV | | Global Fund | Hetero | Macl eods | | | | | | |
| 10mg/ml oral suspension | 10 mL | POA | | \$34 (\$0.009) | \$35 (\$0.01 0) | \$46 (\$0.0 13) | | | | | | |
| lopinavir/riton avir (LPV/r) | | AbbVie | | Global Fund | Aurobi ndo | Cipla | Hetero | Myla n | | | | |
| | | Cat 1 | Cat 2 | | | | | | | | | |
| 40mg/10mg granules | 4 | N/A | | \$206 (\$0.141) | | | | \$220 (\$0.1 51) | | | | |
| 40mg/10mg pellets | 4 | N/A | | \$210 (\$0.144) | | \$219 (\$0.1 50) | | | | | | |
| 100/25mg tablet | 3 | \$119 (\$0.108) | \$278 (\$0.2 54) | \$100 (\$0.092) | \$128 (\$0.11 7) | | \$146 (\$0.133) | \$128 (\$0.1 17) | | | | |
| 200/50mg tablet | 4 | \$243 (\$0.167) | \$740 (\$0.5 07) | \$218 (\$0.150) | \$231 | | \$304 (\$0.208) | \$227 (\$0.1 55) | | | | |

| | | | | | | | | | | |
|---------------------------------|------|------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|----------------|----------------|--|
| | | | | | (\$0.158) | | | | | |
| nevirapine (NVP) | | Boehringer Ingelheim | | Global Fund | Aurobindo | Cipla | | | | |
| 10mg/ml suspension | 20mL | N/A | | \$128 (\$0.018) | \$128 (\$0.018) | \$116 (\$0.016) | | | | |
| 50mg tablet for oral suspension | 4 | N/A | | | | \$48 (\$0.033) | | | | |
| raltegravir (RAL) | | Merck | | Global Fund | | | | | | |
| | | Cat 1 | Cat 2 | | | | | | | |
| 100mg powder/sachet | 2 | \$694 (\$0.95) | N/A | N/A | | | | | | |
| 25mg tablet | XX | (\$0.300) | Case-by-case | | | | | | | |
| 100mg tablet | XX | (\$0.600) | | | | | | | | |
| 400mg tablet | 2 | \$675 (\$0.925) | | | | | | | | |
| ritonavir (RTV) | | Abbvie | | Global Fund | Cipla | Hetero | Mylan | | | |
| | | Cat 1 | Cat 2 | | | | | | | |
| 25mg tablet | | NA | | (\$0.10) | | | (\$0.10) | | | |
| 100mg tablet | 1 | \$91 (\$0.125) | \$624 (\$0.855) | \$170 (\$0.233) | \$155 (\$0.213) | \$170 (\$0.233) | \$170 (\$0.233) | | | |
| tenofovir (TDF) | | Gilead | | Global Fund | Aurobindo | Hetero | Macleods | Mylan | Strides | |
| 300mg tablet | 1 | No response at time of publication | | \$29 (\$0.080) | \$49 (\$0.133) | \$30 (\$0.083) | \$37 (\$0.100) | \$23 (\$0.062) | \$37 (\$0.100) | |

| | | | | | | | | | | | | |
|----------------------------------|------|------------------------------------|--------------------|--------------------|--------------------|-------------------|--------------------|--------------------|--------------------|-------------------|-------------------|-------------------|
| zidovudine (AZT) | | ViiV | Global Fund | Aurobindo | Cipla | Hetero | | | | | | |
| 10mg/ml oral solution | 24mL | POA | \$91 (\$0.010) | \$73 (\$0.008) | \$171 (\$0.020) | \$84 (\$0.010) | | | | | | |
| ABC/3TC | | ViiV | Global Fund | Aurobindo | Cipla | Hetero | Macleods | Mylan | Sun | | | |
| 120/60mg dispersible tablet | 2 | N/A | \$65 (\$0.089) | | \$74 (\$0.101) | | | \$79 (\$0.108) | | | | |
| 600/300mg tablet | 1 | POA | \$96 (\$0.262) | \$110 (\$0.300) | | \$97 (\$0.267) | \$111 (\$0.303) | \$116 (\$0.317) | \$108 (\$0.297) | | | |
| ABC/3TC/DTG | | ViiV | Global Fund | Aurobindo | | | | | | | | |
| 60mg/30mg/5mg dispersible tablet | 1 | N/A | \$120 (\$0.083) | | | | | | | | | |
| 600mg/300mg/50mg tablet | 1 | POA | \$243 (\$0.667) | \$243 (\$0.667) | | | | | | | | |
| TDF/FTC | | Gilead | Global Fund | Cipla | Emcure | Hetero | Lupin | Macleods | Micro | Mylan | Strides | Sun |
| 300/200mg tablet | 1 | No response at time of publication | \$40 (\$0.111) | \$58 (\$0.158) | \$46 (\$0.127) | \$49 (\$0.133) | \$47 (\$0.128) | \$61 (\$0.167) | \$58 (\$0.158) | \$47 (\$0.128) | \$49 (\$0.133) | \$44 (\$0.120) |
| TDF/3TC | | No originator | Global Fund | Cipla | Hetero | Lupin | Micro | Mylan | Sun | Macleods | | |
| 300/300mg tablet | 1 | | \$38 (\$0.104) | \$54 (\$0.147) | \$43 (\$0.117) | \$50 (\$0.138) | \$43 | \$40 (\$0.108) | \$40 (\$0.110) | \$49 (\$0.133) | | |

